Consensus for anticoagulant therapy for cardiomyopathy in China

Title: Consensus for anticoagulant therapy for cardiomyopathy in China
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users: clinical physician
Evidence classification method: Suitable for application: the clinical benefit is clear and should be given priority (equivalent to class I recommendation); Prefer application: most of them can benefit clinically, with good effect, and can be applied in most cases (equivalent to class IIa recommendation); Uncertain application: the evidence of treatment benefit is insufficient, and the application can be weighed according to the actual clinical situation (equivalent to class IIB recommendation); Not suitable for application: clinical application may not be beneficial or damaged, so it is not recommended (equivalent to class III recommendation).
Development unit: 中华医学会心血管病学分会精准心血管病学学组
Registration time: 2021-10-08
Registration number: IPGRP-2021CN320
Purpose of the guideline: Due to the special structural characteristics of cardiomyopathy, the risk of thrombosis / embolism is significantly increased. Accordingly, the use of anticoagulants in patients with high-risk thrombotic cardiomyopathy is significantly insufficient. At present, there are some treatment suggestions or recommendations for anticoagulation schemes for various cardiomyopathy abroad, but there is still no unified anticoagulation guidelines or expert consensus for cardiomyopathy. This expert consensus systematically expounds the anticoagulant indications and schemes of various cardiomyopathy, and makes recommendations according to the existing evidence, to promote and standardize the formulation of anticoagulant treatment schemes for patients with cardiomyopathy and guide clinical application.